(S (NP (NML (NNP Hepatitis) (NNP C)) (NN virus) (PRN (-LRB- -LRB-) (NP (NN HCV)) (-RRB- -RRB-)) (NN infection)) (VP (VBZ is) (ADJP (JJ endemic) (PP (IN in) (NP (NP (NNS people)) (SBAR (WHNP (WP who)) (S (VP (VBP inject) (NP (NNS drugs)) (PRN (-LRB- -LRB-) (NP (NN PWID)) (-RRB- -RRB-)) (, ,) (PP (IN with) (NP (NP (NN prevalence) (NNS estimates)) (PP (IN above) (NP (NP (CD 60) (NN percent)) (PP (IN for) (NP (NP (NNP PWID)) (PP (IN in) (NP (DT the) (NNP United) (NNP States)))))))))))))))) (. .))
(S (S (NP (JJ Previous) (NN modeling) (NNS studies)) (VP (VBP suggest) (SBAR (IN that) (S (NP (JJ direct) (NN acting) (JJ antiviral) (-LRB- -LRB-) (NN DAA) (-RRB- -RRB-) (NN treatment)) (VP (MD can) (VP (VB lower) (NP (JJ overall) (NN prevalence)) (PP (IN in) (NP (DT this) (NN population))))))))) (, ,) (CC but) (S (NP (NN treatment)) (VP (VBZ is) (ADVP (RB often)) (VP (VBN delayed) (PP (IN until) (NP (NP (DT the) (NN onset)) (PP (IN of) (NP (NML (JJ advanced) (NN liver)) (NN disease) (PRN (-LRB- -LRB-) (UCP (NP (NN fibrosis) (NML (NN stage) (CD 3))) (CC or) (ADVP (RB later))) (-RRB- -RRB-)))))) (PP (IN due) (PP (IN to) (NP (NN cost))))))) (. .))
(S (NP (NP (JJR Lower) (NN cost) (NNS interventions)) (VP (VBG featuring) (NP (NP (NN syringe) (NN access) (PRN (-LRB- -LRB-) (NP (NNP SA)) (-RRB- -RRB-))) (CC and) (NP (NP (NP (ADJP (RB medically) (VBN assisted)) (NN treatment)) (-LRB- -LRB-) (NP (NN MAT)) (-RRB- -RRB-)) (PP (IN for) (NP (NN addiction))))))) (VP (VP (VBP are) (VP (VBN known) (S (VP (TO to) (VP (VB be) (ADJP (RBR less) (JJ costly))))))) (, ,) (CC but) (VP (VBP have) (VP (VBN shown) (NP (JJ mixed) (NNS results)) (PP (IN in) (S (VP (VBG lowering) (NP (NN HCV) (NNS rates)) (PP (IN below) (NP (JJ current) (NNS levels))))))))) (. .))
(S (S (NP (JJ Little)) (VP (VBZ is) (VP (VBN known) (PP (IN about) (NP (NP (DT the) (JJ potential) (JJ synergistic) (NNS effects)) (PP (IN of) (S (VP (VBG combining) (NP (NML (NN DAA) (CC and) (NN MAT)) (NN treatment)))))))))) (, ,) (CC and) (S (NP (NP (NML (JJ large) (HYPH -) (NN scale)) (NNS tests)) (PP (IN of) (NP (VBN combined) (NNS interventions)))) (VP (VBP are) (ADJP (JJ rare)))) (. .))
(S (SBAR (IN While) (S (NP (NN simulation) (NNS experiments)) (VP (MD can) (VP (VB reveal) (NP (JJ likely) (NML (JJ long) (HYPH -) (NN term)) (NNS effects)))))) (, ,) (NP (JJS most) (JJ prior) (NNS simulations)) (VP (VBP have) (VP (VBN been) (VP (VBN performed) (PP (IN on) (NP (NP (JJ closed) (NNS populations)) (PP (IN of) (NP (NN model) (NNS agents))))) (: --) (S (NP (DT a) (NN scenario)) (ADJP (RB quite) (JJ different) (PP (IN from) (NP (NP (DT the) (JJ open) (, ,) (JJ mobile) (NNS populations)) (VP (VBN known) (PP (IN to) (NP (JJS most) (NN health) (NNS agencies))))))))))) (. .))
(S (NP (DT This) (NN paper)) (VP (VBZ uses) (NP (NNS data)) (PP (IN from) (NP (DT the) (NNPS Centers))) (PP (IN for) (NP (NP (NP (NNP Disease) (NNP Control) (POS 's)) (NML (NNP National) (NNP HIV)) (JJ Behavioral) (NN Surveillance) (NN project)) (, ,) (NP (NP (NP (NNP IDU)) (NP (RB round) (CD 3))) (, ,) (VP (VBN collected) (PP (IN in) (NP (NP (NNP New) (NNP York) (NNP City)) (PP (IN in) (NP (CD 2012))))) (PP (IN by) (NP (DT the) (NML (NNP New) (NNP York)) (NML (NML (NNP City) (NNP Department)) (PP (IN of) (NP (NNP Health) (CC and) (NNP Mental)))) (NNP Hygiene))) (S (VP (TO to) (VP (VB parameterize) (NP (NP (NNS simulations)) (PP (IN of) (NP (JJ open) (NNS populations)))))))))))) (. .))
(S (NP (PRP$ Our) (NNS results)) (VP (VBP show) (SBAR (IN that) (S (, ,) (PP (IN in) (NP (DT an) (JJ open) (NN population))) (, ,) (NP (NP (NNP SA) (HYPH /) (NNP MAT)) (PP (IN by) (NP (PRP itself)))) (VP (VBZ has) (NP (NP (RB only) (JJ small) (NNS effects)) (PP (IN on) (NP (NNP HCV) (NN prevalence)))) (, ,) (SBAR (IN while) (S (NP (NP (NN DAA) (NN treatment)) (PP (IN by) (NP (PRP itself)))) (VP (MD can) (ADVP (RB significantly)) (VP (VB lower) (NP (DT both) (ADJP (NP (NP (NNP HCV)) (CC and) (NP (NNP HCV))) (HYPH -) (VBN related)) (NML (JJ advanced) (NN liver)) (NN disease) (NN prevalence)))))))))) (. .))
(S (ADVP (RBR More) (RB importantly)) (, ,) (NP (DT the) (NN simulation) (NNS experiments)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (ADJP (NN cost) (JJ effective)) (ADJP (JJ synergistic)) (NNS combinations)) (PP (IN of) (NP (DT the) (CD two) (NNS strategies)))) (VP (MD can) (ADVP (RB dramatically)) (VP (VB reduce) (NP (NN HCV) (NN incidence))))))) (. .))
(S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (S (VP (VBG adopting) (NP (NML (NNP SA) (HYPH /) (NNP MAT)) (NNS implementations)) (PP (IN alongside) (NP (NN DAA) (NNS interventions))))) (VP (MD can) (VP (VB play) (NP (DT a) (JJ critical) (NN role)) (PP (IN in) (S (VP (VBG reducing) (NP (NP (DT the) (NML (JJ long) (HYPH -) (NN term)) (NNS consequences)) (PP (IN of) (NP (JJ ongoing) (NN infection)))))))))))) (. .))
